Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
1. Altimmune shares fell 61.2% to $2.99 after trial results. 2. IMPACT Phase 2b trial results for Pemvidutide were disappointing. 3. Overall U.S. stock futures rose, but ALT sharply declined. 4. Other stocks also saw declines in pre-market trading. 5. Market reactions indicate broader investor concerns.